SFS
DNLI icon

Sowell Financial Services’s Denali Therapeutics DNLI Stock Holding History

Sowell Financial Services’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-160
Closed -$9K – 1078
2021
Q1 		$9K Hold
160
– – ﹤0.01% 2357
2020
Q4 		$13K Buy
+160
New +$9.67K ﹤0.01% 1907

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sowell Financial Services's DNLI Position: Q2 2021 in Review

Sowell Financial Services sold out of Denali Therapeutics (DNLI) in Q2 2021, closing a stake of 160 shares — an estimated $9K sold.

Sowell Financial Services first reported a position in DNLI in Q4 2020 and held it in 2 quarters. The position peaked at $13K in Q4 2020. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

  • Sowell Financial Services reported no remaining Denali Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 160 Denali Therapeutics shares in Q2 2021, an estimated $9K.
  • Sowell Financial Services first reported a position in Denali Therapeutics in Q4 2020 and held it in 2 quarters.
  • Sowell Financial Services's Denali Therapeutics position peaked at $13K in Q4 2020.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.